Grifols
NEWS
While the trial was designed to test safety and not efficacy, patients treated with Araclon Biotech’s experimental ABvac40 vaccine saw a 38% drop in disease progression compared to placebo.
Spanish drugmaker Grifols announced a comprehensive plan Wednesday to improve its efficiency and cost-effectiveness – a move that will reportedly cost some 2,000 U.S. jobs.
Life Science industries are seeing massive financial fluctuations in how they’re handling the COVID-19 pandemic, but there is some optimism of a recovery by biopharma executives.
Araclon Biotech of Spain revealed positive data from the first part of a phase II trial for its immunotherapeutic vaccine to prevent Alzheimer’s disease- ABvac40.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
It was another busy week for clinical trial announcements. Here’s a look including trials for COVID-19, migraine, Parkinson’s disease, Alzheimer’s, HIV and more.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
The transaction, which is set to conclude in early 2021, will give Grifols access to Alkahest’s four product candidates.
JOBS
IN THE PRESS